Education
About Us
Working with TipRanks
Follow Us
Carmat SA (FR:ALCAR)
:ALCAR
Top Page
Carmat SA
(ALCAR)
Select Model
Select Model
Rating:40Underperform
Price Target:
€0.09
▼(-6.00% Downside)
The score is driven primarily by very weak financial performance—large ongoing losses, heavy cash burn, and a strained balance sheet with negative equity and meaningful debt—creating significant funding/solvency risk. Technicals are also bearish (downtrend with negative MACD), with oversold indicators offering only limited offset. Valuation is constrained by a negative P/E and no indicated dividend yield.
Carmat SA (ALCAR) vs. iShares MSCI France ETF (EWQ)
Market Cap
€6.35M
Dividend YieldN/A
Average Volume (3M)288.93K
Price to Earnings (P/E)―
Beta (1Y)0.98
Revenue GrowthN/A
EPS GrowthN/A
CountryFR
Employees162
SectorHealthcare
Sector Strength45
IndustryMedical - Devices
Share Statistics
EPS (TTM)N/A
Shares Outstanding64,254,005
10 Day Avg. Volume0
30 Day Avg. Volume288,932
Financial Highlights & Ratios
PEG Ratio0.11
Price to Book (P/B)-0.49
Price to Sales (P/S)3.55
P/FCF Ratio-0.55
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Carmat SA Business Overview & Revenue Model
Company DescriptionCarmat SA designs and develops total artificial heart for people suffering from end-stage biventricular heart failure in France and internationally. It The company was founded in 2008 and is headquartered in Vélizy-Villacoublay, France.
How the Company Makes Money
Carmat SA Financial Statement Overview
Summary
Income Statement
Balance Sheet
Cash Flow
| Breakdown | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 7.00M | 2.85M | 345.00K | 2.23M | 9.00K |
| Gross Profit | 0.00 | -30.97M | -54.15M | -52.48M | -20.08M |
| EBITDA | -49.80M | -50.45M | -50.24M | -59.10M | -35.48M |
| Net Income | -51.40M | -53.87M | -53.68M | -61.87M | -36.96M |
Balance Sheet | |||||
| Total Assets | 42.43M | 53.07M | 85.07M | 68.91M | 59.84M |
| Cash, Cash Equivalents and Short-Term Investments | 4.70M | 8.01M | 51.43M | 39.19M | 35.98M |
| Total Debt | 57.80M | 57.65M | 52.11M | 54.62M | 38.94M |
| Total Liabilities | 93.56M | 96.83M | 83.27M | 82.63M | 52.02M |
| Stockholders Equity | -51.13M | -45.11M | 1.65M | -13.72M | 7.82M |
Cash Flow | |||||
| Free Cash Flow | -44.82M | -58.51M | -56.37M | -61.93M | -45.36M |
| Operating Cash Flow | -43.31M | -53.48M | -54.38M | -60.17M | -43.03M |
| Investing Cash Flow | -1.45M | -4.92M | -1.99M | -1.75M | -2.30M |
| Financing Cash Flow | 41.45M | 14.98M | 68.60M | 65.13M | 25.81M |
Carmat SA Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
50 Neutral | €25.66M | -6.58 | -16.42% | ― | 138.92% | 11.14% | |
48 Neutral | €73.14M | -5.06 | -62.69% | ― | ― | 30.04% | |
47 Neutral | €34.23M | -6.58 | -450.14% | ― | 52.11% | 68.65% | |
45 Neutral | €35.47M | -4.77 | -2351.12% | ― | -4.70% | -64.31% | |
40 Underperform | €6.35M | -0.08 | ― | ― | ― | ― |
* Healthcare Sector Average
FR:ALCAR
Carmat SA
0.10
-0.96
-90.68%
FR:ALTHE
Theraclion SA
0.61
0.38
165.22%
FR:ALIKO
Ikonisys SA
1.56
0.08
5.41%
FR:ALEMG
Euromedis Groupe SA
3.92
-0.48
-10.91%
FR:AFME
Affluent Medical SA
1.90
0.50
35.71%
FR:ALIMP
Implanet SA
0.25
0.12
92.31%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.